Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Too Much RNA Can Actually Starve Cells of Energy, Study Finds

RNA, or ribonucleic acid, is one of the most important molecules in keeping the body functioning correctly. One of its main jobs is to turn the information stored in our genetics into actual proteins that build and operate cells, for example.

To stay healthy, cells keep RNA production and deletion in a careful balance, but there are ways this balance can be tipped over. Invading viruses tend to produce more RNA, and aging, certain cancers, and neurodegenerative diseases can also cause disruption.

In a study published in PNAS, researchers outline a newly discovered way that too much RNA can cause harm: It can interfere with tiny power plants called mitochondria inside cells, limiting their energy production capacities.

Could Drugs for Diabetes and ADHD Offer New Hope for Alzheimer’s Patients?

The AD-SMART trial will initially test two repurposed medicines. One is metformin, widely used to treat type 2 diabetes. The other is atomoxetine, a drug prescribed for attention deficit hyperactivity disorder, or ADHD. An international expert panel selected these drugs based on early evidence that they may reduce brain inflammation, which scientists believe is one of the drivers of neurodegeneration in Alzheimer’s disease.

Professor Paresh Malhotra, chief investigator of the study and group leader at the UK Dementia Research Institute Centre for Care Research & Technology at Imperial College London, described a central problem in Alzheimer’s research. He noted that for too long progress has followed a pattern of one drug, one trial, one answer, often taking a decade or more for each attempt. AD-SMART is a deliberate effort to break this pattern and accelerate the path to answers for patients and families.

The design of the trial is particularly notable. AD-SMART is a multi-arm, multi-stage platform trial. Instead of testing a single drug against a placebo over many years, it evaluates several treatments at the same time against one shared placebo group. People who join the study have a higher chance of receiving an active treatment compared with many traditional trials, where a large proportion of participants might receive a placebo alone.

Revisiting post-stimulus theta activity: evidence for a broadband rather than narrowband spectral origin

The aperiodic, 1/f-like component of electrophysiological activity is increasingly recognized as a meaningful feature of neural function rather than background noise. Meanwhile, many EEG studies interpret transient post-stimulus changes in oscillatory power as signatures of attention, salience, or cognitive control. Such interpretations typically depend on baseline normalization, which assumes aperiodic activity remains stable from pre-to post-stimulus periods. Using high-density EEG from typically developing children, we tested this assumption across two paradigms: an audiovisual simple reaction-time task (n = 36, 19 males and 17 females) and a visual oddball task (n = 38, 20 males and 18 females). In each, conventional spectral analyses were compared with analyses that explicitly modeled and removed aperiodic activity in both windows. Across tasks, stimulus onset produced robust increases in aperiodic exponent and offset, indicating systematic 1/f changes. In the audiovisual task these were modality-specific, with central, parieto-occipital, or combined topographies by stimulus type. They diminished but persisted after ERP removal, suggesting they were not fully explained by phase-locked activity. Critically, once aperiodic activity was accounted for, the apparent theta increase was largely abolished in both tasks, including the canonical fronto-central enhancement to infrequent targets. The conventional method also overestimated beta desynchronization, especially in the induced signal, indicating a spurious consequence of spectral slope steepening. By contrast, alpha desynchronization remained robust and was enhanced, reflecting genuine suppression. Together, these findings suggest many conventional time-frequency effects, particularly apparent theta synchronization, may reflect stimulus-driven aperiodic changes rather than robust narrowband changes, challenging core assumptions of these analyses.

Significance statement Frequency-domain neural activity comprises both narrowband oscillations and broadband aperiodic activity. Conventional time–frequency analyses use baseline normalization to isolate oscillatory responses, implicitly assuming that aperiodic activity remains stable following stimulus onset. Across two EEG paradigms, we show that stimulus presentation systematically alters aperiodic activity in a sensory-and attention-dependent manner. These changes can produce apparent increases in theta-band power that do not reflect genuine narrowband oscillations and can exaggerate beta desynchronization. In contrast, alpha desynchronization remained robust after accounting for aperiodic activity. These findings demonstrate that stimulus-related aperiodic changes can substantially influence conventional time–frequency measures and should be explicitly considered when interpreting post-stimulus oscillatory responses.

A tiny defect in a crystal reveals a big quantum surprise

Researchers have solved a long-standing challenge in understanding how tiny defects in materials like diamond and silicon carbide behave when exposed to light. Their new computational method revealed a surprisingly important energy-loss mechanism in silicon carbide that scientists had previously underestimated. The finding helps explain a mystery that has puzzled researchers for years and could improve the design of quantum computers and sensors.

Stanford scientist discusses Nobel Prize-winning work in neuroscience

Stanford University scientist Dr. Karl Deisseroth, who recently won the Nobel Prize in Physiology or Medicine, joined California Tonight to discuss his groundbreaking work in a revolutionary field in neuroscience that holds promise for treating conditions from autism to schizophrenia.

Optogenetics, the field for which Deisseroth and two colleagues were honored, uses light to both map and control very specific parts of the brain. He explained, “It’s the opposite of how you normally think about imaging. We think about using light to collect information, but this is using light to make things happen, to control things. The beauty of that is that we can make it very precise, much more precise than an electrode or medication could be. And we do this, here’s the twist, we borrow a gene from a single-celled organism, a microbe that happens to make a beautiful little protein, a little biomolecule that’s a light-activated regulator of electricity.”

Exploring the potential of regenerative medicine

The science of ageing is an area of intense activity, offering the possibility of extending healthspan as well as lifespan. Saisei Pharma, a Japanese biotechnology company founded in 2014, is asking big questions about the potential of regenerative medicine. Here, Toshio Inui, CEO of Saisei Mirai Group, and a visiting professor at Kagoshima University in Kyushu, Japan, explains why recent advances in ageing research are so exciting.

Why is ageing research important?

Ageing is the single greatest common risk factor for many chronic diseases. As we age, our physical functions decline and we become more prone to develop age-related diseases, such as dementia, cancer, cardiovascular conditions, diabetes and impaired kidney function.